Want to see JP:4591 full AI Analyst Report?
Ribomic, Inc. (4591) AI Stock Analysis
Ribomic, Inc.
(TSE/TYO:4591)
The score is primarily held back by weak financial performance driven by ongoing losses and cash burn, only partly mitigated by a debt-free, net-cash balance sheet. Technical conditions are also soft with the stock trading below key moving averages and negative MACD. Valuation provides limited support due to the negative P/E and no dividend yield data.
Ribomic, Inc. (4591) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.45B
- Dividend Yield
- ―
- Average Volume (3M)
- 620.70K
- Price to Earnings (P/E)
- -2.5
- Beta (1Y)
- 0.44
- Revenue Growth
- 1135.58%
- EPS Growth
- 2.37%
- Country
- Japan
- Employees
- 25
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Ribomic, Inc. Business Overview & Revenue Model
Company Description
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macula...
Ribomic, Inc. Financial Statement Overview
Summary
Financials reflect an early-stage biotech profile: persistent large operating/net losses and minimal revenue relative to expenses (weak income statement), alongside ongoing negative operating and free cash flow (continued cash burn). The main offset is a net-cash, zero-debt balance sheet, but equity has been trending down, indicating losses are eroding the capital base.
Income Statement
14Very NegativeBalance Sheet
62PositiveCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.50M | 3.00M | 2.11M | 0 | 65.97M | 80.91M |
| Gross Profit | 3.85M | -995.00K | 1.19M | -10.50M | 0 | 0 |
| EBITDA | -1.23B | -1.20B | -1.05B | -1.11B | -1.79B | -1.73B |
| Net Income | -1.19B | -1.15B | -1.02B | -1.02B | -1.65B | -1.68B |
Balance Sheet | ||||||
| Total Assets | 2.89B | 2.98B | 3.19B | 3.55B | 4.58B | 4.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.78B | 2.83B | 3.04B | 3.40B | 4.33B | 4.70B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 150.03M | 135.09M | 142.21M | 155.81M | 199.30M | 260.53M |
| Stockholders Equity | 2.74B | 2.84B | 3.04B | 3.39B | 4.38B | 4.69B |
Cash Flow | ||||||
| Free Cash Flow | -255.11M | -1.12B | -1.03B | -955.48M | -1.73B | -1.51B |
| Operating Cash Flow | -250.76M | -1.11B | -996.97M | -932.76M | -1.71B | -1.50B |
| Investing Cash Flow | -54.35M | 289.83M | 67.18M | 177.27M | 276.35M | 689.56M |
| Financing Cash Flow | 347.70M | 911.05M | 667.26M | 27.65M | 1.33B | 354.72M |
Ribomic, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4591, the sentiment is Negative. The current price of 60.00 is below the 20-day moving average (MA) of 67.35, below the 50-day MA of 76.32, and below the 200-day MA of 78.86, indicating a bearish trend. The MACD of -3.49 indicates Negative momentum. The RSI at 31.24 is Neutral, neither overbought nor oversold. The STOCH value of 27.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4591.
Ribomic, Inc. Peers Comparison
Overall Rating
JP:218350Neutral- JP:459146Neutral
JP:457142Neutral
JP:458741.5Neutral
JP:457539Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:2183 | 50Neutral | JPY 4.49B | -1.17 | ― | 4.06% | -21.55% | -497.97% |
| JP:4591 | 46Neutral | JPY 3.60B | -2.45 | ― | ― | 1135.58% | 2.37% |
| JP:4571 | 42Neutral | JPY 7.10B | -5.05 | -33.61% | ― | 74.24% | -7.78% |
| JP:4587 | 42Neutral | JPY 143.59B | -37.57 | -7.17% | ― | 0.62% | 27.66% |
| JP:4575 | 39Underperform | JPY 14.00B | -10.04 | ― | ― | ― | -8.52% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4591 | Ribomic, Inc. | 60.00 | -30.00 | -33.33% | |
| JP:4587 | Peptidream | 1143.00 | -382.50 | -25.07% | |
| JP:4571 | NanoCarrier Co., Ltd. | 74.00 | -84.00 | -53.16% | |
| JP:2183 | Linical Co., Ltd. | 197.00 | -143.48 | -42.14% | |
| JP:4575 | CanBas Co., Ltd. | 668.00 | -132.00 | -16.50% |
Ribomic, Inc. Corporate Events
Ribomic Signs Foreign DDS Aptamer Evaluation Deal, Updates FY 2027 Outlook
Ribomic, Inc. has entered a technology evaluation agreement with an undisclosed foreign biotechnology company to test its proprietary DDS aptamer platform, marking the sixth such deal under its drug discovery support business. Under the arrangement,...
Ribomic Reports Sustained Growth Benefits in Interim Phase 2 Data for Achondroplasia Drug
Ribomic reported interim results from a phase 2 long-term trial of umedaptanib pegol in pediatric patients with achondroplasia, covering 11 participants who entered extended dosing and seven who remain on treatment. The company said sustained growth...
RIBOMIC Reports Early Safety Data for Umedaptanib Pegol in Achondroplasia Study
RIBOMIC reported that no safety concerns have emerged after three months of weekly 1 mg/kg subcutaneous treatment with umedaptanib pegol in a pediatric achondroplasia Phase 2 long-term extension study. The update covers the first participant who tran...
Ribomic Completes Site Network for Phase 3 Achondroplasia Trial in Japan
Ribomic has completed the establishment of all planned clinical trial sites for its Phase 3 study of umedaptanib pegol in paediatric achondroplasia patients in Japan, securing Institutional Review Board approval at six additional locations to reach a...
Ribomic Posts Quarterly Loss but Maintains Strong Equity Base and Full-Year Outlook
Ribomic reported non-consolidated results for the quarter ended June 30, 2026, posting modest operating revenue of ¥4 million and a net loss of ¥270 million, slightly narrower in per-share terms than the prior-year period. Total assets decl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026